Vivani Medical (NASDAQ:VANI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Vivani Medical (NASDAQ:VANI) from a sell rating to a hold rating in a research report released on Saturday morning.

Other research analysts have also issued research reports about the stock. Weiss Ratings upgraded shares of Vivani Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 7th. Lake Street Capital began coverage on shares of Vivani Medical in a research report on Tuesday, June 23rd. They set a “buy” rating and a $4.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.75.

Vivani Medical Trading Down 3.6%

Shares of NASDAQ VANI opened at $1.35 on Friday. The company has a market capitalization of $116.42 million, a P/E ratio of -3.86 and a beta of 2.35. Vivani Medical has a 12 month low of $0.92 and a 12 month high of $1.92. The stock has a 50 day moving average of $1.30 and a 200-day moving average of $1.24.

Vivani Medical (NASDAQ:VANI) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Analysts predict that Vivani Medical will post -0.3 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Gregg Williams bought 1,587,301 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was bought at an average price of $1.26 per share, with a total value of $1,999,999.26. Following the completion of the acquisition, the director owned 36,119,086 shares of the company’s stock, valued at $45,510,048.36. This represents a 4.60% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 53.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Vivani Medical

A number of institutional investors have recently modified their holdings of VANI. State Street Corp increased its position in Vivani Medical by 12.5% during the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after acquiring an additional 16,070 shares during the period. Susquehanna International Group LLP raised its stake in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after purchasing an additional 16,200 shares in the last quarter. Citadel Advisors LLC bought a new stake in Vivani Medical in the 3rd quarter valued at about $26,000. Jane Street Group LLC bought a new stake in Vivani Medical in the 4th quarter valued at about $60,000. Finally, Renaissance Technologies LLC grew its position in shares of Vivani Medical by 118.4% during the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after purchasing an additional 53,127 shares in the last quarter. Institutional investors own 6.78% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.